{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T22:52:50Z","timestamp":1781045570802,"version":"3.54.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,31]],"date-time":"2022-12-31T00:00:00Z","timestamp":1672444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,31]],"date-time":"2022-12-31T00:00:00Z","timestamp":1672444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Changzhou Science and Technology Project","award":["QN202114"],"award-info":[{"award-number":["QN202114"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diagn Pathol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Secretory breast carcinoma (SBC) is a rare malignant breast neoplasm with distinct histological features, including solid, microcystic, tubular, and rarely papillary structures, traditionally characterized by a t (12;15) (p13:q25) translocation, which usually leads to<jats:italic>ETV6-NTRK3<\/jats:italic>fusion, suggesting an early event in tumorigenesis. Due to the rarity of this disease, very few genome sequencing studies have been performed on a series of cases, especially progressive cases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Seven lesions from 5 patients diagnosed at the Third Affiliated Hospital of Soochow University from 2007 to 2021 were included. Clinicopathological features and prognosis\/survival data were collected. Next-generation DNA sequencing was performed on six of the seven lesions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 3\/7 (42.9%) lesions demonstrated estrogen receptor (ER) expression, including weak, moderate to strong staining, and no lesion demonstrated progesterone receptor (PR) expression. There were no cases of human epidermal growth factor (HER2) overexpression, and the Ki-67 index was low. S-100 and pan-TRK protein were diffusely positively expressed in all cases. All lesions were characterized by a t(12;15) (p13:q25) translocation, leading to<jats:italic>ETV6-NTRK3<\/jats:italic>fusion confirmed by fluorescence in situ hybridization (FISH). The sequencing results showed that<jats:italic>ETV6-NTRK3<\/jats:italic>fusion was the main driver of early tumorigenesis, while SBC with invasive biological behavior had more complex genomic variation in which<jats:italic>TERT<\/jats:italic>promoter mutation was detected.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Immunohistochemical staining of a biomarker panel, including ER, PR, HER2, Ki-67, S-100 and pan-TRK, can be used as an auxiliary diagnostic tool, and FISH detection can be used as a diagnostic tool.<jats:italic>ETV6-NTRK3<\/jats:italic>gene fusion involving multiple sites may drive tumorigenesis, while mutations in the<jats:italic>TERT<\/jats:italic>promoter region may be a factor driving tumor progression.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13000-022-01284-7","type":"journal-article","created":{"date-parts":[[2022,12,31]],"date-time":"2022-12-31T04:30:54Z","timestamp":1672461054000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Clinicopathological features and genomic profiles of a group of secretory breast carcinomas in which progressive cases have more complex genomic features"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2278-9965","authenticated-orcid":false,"given":"Ting","family":"Lei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqiang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0311-7074","authenticated-orcid":false,"given":"Tongbing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,31]]},"reference":[{"key":"1284_CR1","unstructured":"Rakha EA R-FJ, Sasano H, Wu Y; WHO classifcation of tumours editorial board: Breast tumours. WHO classifcation of tumours series, 5th ed.; 2019."},{"key":"1284_CR2","doi-asserted-by":"publisher","first-page":"153790","DOI":"10.1016\/j.prp.2022.153790","volume":"231","author":"M Chen","year":"2022","unstructured":"Chen M, Pu T, Wei B, Bu H, Tang P, Zhang Z. Genomic landscape of secretory carcinoma of the breast with axillary lymph node metastasis. Pathol Res Pract. 2022;231:153790.","journal-title":"Pathol Res Pract"},{"issue":"1","key":"1284_CR3","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.anndiagpath.2012.06.001","volume":"17","author":"NU Din","year":"2013","unstructured":"Din NU, Idrees R, Fatima S, Kayani N. Secretory carcinoma of breast: clinicopathologic study of 8 cases. Ann Diagn Pathol. 2013;17(1):54\u20137.","journal-title":"Ann Diagn Pathol"},{"key":"1284_CR4","doi-asserted-by":"crossref","unstructured":"Castillo MD, Chibon F, Arnould L, Croce S, Ribeiro A, Perot G, et al. Secretory Breast Carcinoma: A Histopathologic and Genomic Spectrum Characterized by a Joint Specific ETV6-NTRK3 Gene Fusion. Am J Surg Pathol.\u00a02015;39(11):1458\u201367.","DOI":"10.1097\/PAS.0000000000000487"},{"issue":"8","key":"1284_CR5","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1038\/modpathol.2017.32","volume":"30","author":"G Krings","year":"2017","unstructured":"Krings G, Joseph NM, Bean GR, Solomon D, Onodera C, alevich E, et al.\u00a0Genomic profiling of breast secretory carcinomas reveals distinct genetics from other breast cancers and similarity to mammary analog secretory carcinomas. Mod Pathol. 2017;30(8):1086\u201399.","journal-title":"Mod Pathol"},{"issue":"5","key":"1284_CR6","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S1535-6108(02)00180-0","volume":"2","author":"SRK Cristina Tognon","year":"2002","unstructured":"Tognon C, Knezevich SR, Huntsman D, Roskelley CD, Melnyk N, Mathers JA,\u00a0et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell. 2002;2(5):367\u201376.","journal-title":"Cancer Cell"},{"issue":"2","key":"1284_CR7","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/modpathol.2008.184","volume":"22","author":"M Lae","year":"2009","unstructured":"Lae M, Freneaux P, Sastre-Garau X, Chouchane O, Sigal-Zafrani B, Vincent-Salomon A. Secretory breast carcinomas with ETV6-NTRK3 fusion gene belong to the basal-like carcinoma spectrum. Mod Pathol. 2009;22(2):291\u20138.","journal-title":"Mod Pathol"},{"issue":"1","key":"1284_CR8","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13000-019-0872-7","volume":"14","author":"Y Yang","year":"2019","unstructured":"Yang Y, Wang Z, Pan G, Li S, Wu Y, Liu L. Pure secretory carcinoma in situ: a case report and literature review. Diagn Pathol. 2019;14(1):95.","journal-title":"Diagn Pathol"},{"issue":"12","key":"1284_CR9","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.5858\/arpa.2010-0351-RS","volume":"135","author":"P Vasudev","year":"2011","unstructured":"Vasudev P, Onuma K. Secretory breast carcinoma: unique, triple-negative carcinoma with a favorable prognosis and characteristic molecular expression. Arch Pathol Lab Med. 2011;135(12):1606\u201310.","journal-title":"Arch Pathol Lab Med"},{"issue":"11","key":"1284_CR10","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1002\/gcc.22767","volume":"58","author":"AJ Suurmeijer","year":"2019","unstructured":"Suurmeijer AJ, Dickson BC, Swanson D, Zhang L, Sung YS, Huang HY, et al. The histologic spectrum of soft tissue spindle cell tumors with NTRK3 gene rearrangements. Genes Chromosomes Cancer. 2019;58(11):739\u201346.","journal-title":"Genes Chromosomes Cancer"},{"issue":"7","key":"1284_CR11","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1136\/jcp.2008.059675","volume":"62","author":"MB Lambros","year":"2015","unstructured":"Lambros MB, Tan DS, Jones RL, Vatcheva R, Savage K, Tamber N, et al. Genomic profile of a secretory breast cancer with an ETV6-NTRK3 duplication. J Clin Pathol. 2015;62(7):604\u201312.","journal-title":"J Clin Pathol"},{"issue":"3","key":"1284_CR12","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/pin.13204","volume":"72","author":"SL Maund","year":"2022","unstructured":"Maund SL, Sokol ES, Ang Houle A, Ross JS, Wilson TR. NTRK gene fusions are detected in both secretory and non-secretory breast cancers. Pathol Int. 2022;72(3):187\u201392.","journal-title":"Pathol Int"},{"issue":"5","key":"1284_CR13","doi-asserted-by":"publisher","first-page":"e1700125","DOI":"10.1002\/prca.201700125","volume":"12","author":"MS Jin","year":"2018","unstructured":"Jin MS, Lee H, Woo J, Choi S, Do MS, Kim K, et al. Integrated Multi-Omic Analyses Support Distinguishing Secretory Carcinoma of the Breast from Basal-Like Triple-Negative Breast Cancer. Proteomics Clin Appl. 2018;12(5):e1700125.","journal-title":"Proteomics Clin Appl"},{"issue":"3","key":"1284_CR14","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.breast.2012.02.013","volume":"21","author":"DP Horowitz","year":"2012","unstructured":"Horowitz DP, Sharma CS, Connolly E, Gidea-Addeo D, Deutsch I. Secretory carcinoma of the breast: results from the survival, epidemiology and end results database. Breast. 2012;21(3):350\u20133.","journal-title":"Breast"},{"issue":"7","key":"1284_CR15","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1002\/jso.24241","volume":"113","author":"JD Jacob","year":"2016","unstructured":"Jacob JD, Hodge C, Franko J, Pezzi CM, Goldman CD, Klimberg VS. Rare breast cancer: 246 invasive secretory carcinomas from the National Cancer Data Base. J Surg Oncol. 2016;113(7):721\u20135.","journal-title":"J Surg Oncol"},{"issue":"1","key":"1284_CR16","doi-asserted-by":"publisher","first-page":"14738","DOI":"10.1038\/s41598-021-94351-w","volume":"11","author":"P Gong","year":"2021","unstructured":"Gong P, Xia C, Yang Y, Lei W, Yang W, Yu J, et al. Clinicopathologic profiling and oncologic outcomes of secretory carcinoma of the breast. Sci Rep. 2021;11(1):14738.","journal-title":"Sci Rep"},{"issue":"10","key":"1284_CR17","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1023\/A:1008387800525","volume":"11","author":"H Herz","year":"2000","unstructured":"Herz H, Cooke B, Goldstein D. Metastatic secretory breast cancer. Non-responsiveness to chemotherapy: case report and review of the literature. Ann Oncol. 2000;11(10):1343\u20137.","journal-title":"Ann Oncol"},{"issue":"2","key":"1284_CR18","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/his.13879","volume":"75","author":"RS Hoda","year":"2019","unstructured":"Hoda RS, Brogi E, Pareja F, Nanjangud G, Murray MP, Weigelt B, et al. Secretory carcinoma of the breast: clinicopathologic profile of 14 cases emphasising distant metastatic potential. Histopathology. 2019;75(2):213\u201324.","journal-title":"Histopathology"},{"issue":"1","key":"1284_CR19","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13000-021-01156-6","volume":"16","author":"J Lian","year":"2021","unstructured":"Lian J, Wang LX, Guo JH, Bu P, Xi YF, Yun KM. Secretory breast carcinoma in a female adult with liver metastsis: a case report and literature review. Diagn Pathol. 2021;16(1):89.","journal-title":"Diagn Pathol"},{"issue":"1","key":"1284_CR20","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13000-021-01115-1","volume":"16","author":"H Tang","year":"2021","unstructured":"Tang H, Zhong L, Jiang H, Zhang Y, Liang G, Chen G, et al. Secretory carcinoma of the breast with multiple distant metastases in the brain and unfavorable prognosis: a case report and literature review. Diagn Pathol. 2021;16(1):56.","journal-title":"Diagn Pathol"},{"issue":"6","key":"1284_CR21","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1002\/gcc.22929","volume":"60","author":"J Xu","year":"2020","unstructured":"Xu J, Weisman P. Dedifferentiated secretory breast carcinoma with fibrosarcomatous features harboring an ETV6-NTRK3 fusion in both components. Genes, Chromosomes and Cancer. 2020;60(6):447\u201351.","journal-title":"Genes, Chromosomes and Cancer"},{"key":"1284_CR22","doi-asserted-by":"crossref","unstructured":"Shukla N, Roberts SS, Baki MO, Mushtaq Q, Goss PE, Park BH, et al. Successful Targeted Therapy of Refractory Pediatric ETV6-NTRK3 Fusion-Positive Secretory Breast Carcinoma. JCO Precis Oncol. 2017;2017:PO.17.00034.","DOI":"10.1200\/PO.17.00034"},{"issue":"2","key":"1284_CR23","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s00428-019-02640-7","volume":"476","author":"D Bell","year":"2020","unstructured":"Bell D, Ferrarotto R, Liang L, Goepfert RP, Li J, Ning J, et al. Pan-Trk immunohistochemistry reliably identifies ETV6-NTRK3 fusion in secretory carcinoma of the salivary gland. Virchows Arch. 2020;476(2):295\u2013305.","journal-title":"Virchows Arch"},{"issue":"43","key":"1284_CR24","first-page":"1693","volume":"2019","author":"T Beth","year":"2019","unstructured":"Harrison BT, Fowler E, Krings G, Chen YY, Bean GR, Vincent-Salomon A, et al. Pan-TRK Immunohistochemistry: A Useful Diagnostic Adjunct For Secretory Carcinoma of the Breast. Am J Surg Pathol. 2019;2019(43):1693\u2013700.","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"1284_CR25","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s40463-018-0315-6","volume":"47","author":"D Forner","year":"2018","unstructured":"Forner D, Bullock M, Manders D, Wallace T, Chin CJ, Johnson LB, et al. Secretory carcinoma: the eastern Canadian experience and literature review. J Otolaryngol Head Neck Surg. 2018;47(1):69.","journal-title":"J Otolaryngol Head Neck Surg"},{"key":"1284_CR26","doi-asserted-by":"publisher","first-page":"e2020227","DOI":"10.4322\/acr.2020.227","volume":"11","author":"N Banerjee","year":"2021","unstructured":"Banerjee N, Banerjee D, Choudhary N. Secretory carcinoma of the breast, commonly exhibits the features of low grade, triple negative breast carcinoma- A Case report with updated review of literature. Autops Case Rep. 2021;11:e2020227.","journal-title":"Autops Case Rep"},{"issue":"4","key":"1284_CR27","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/his.12172","volume":"63","author":"T Osako","year":"2013","unstructured":"Osako T, Takeuchi K, Horii R, Iwase T, Akiyama F. Secretory carcinoma of the breast and its histopathological mimics: value of markers for differential diagnosis. Histopathology. 2013;63(4):509\u201319.","journal-title":"Histopathology"},{"issue":"4","key":"1284_CR28","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/modpathol.2011.190","volume":"25","author":"D Li","year":"2012","unstructured":"Li D, Xiao X, Yang W, Shui R, Tu X, Lu H, et al. Secretory breast carcinoma: a clinicopathological and immunophenotypic study of 15 cases with a review of the literature. Mod Pathol. 2012;25(4):567\u201375.","journal-title":"Mod Pathol"},{"key":"1284_CR29","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.humpath.2021.03.007","volume":"112","author":"LM Weiss","year":"2021","unstructured":"Weiss LM, Funari VA. NTRK fusions and Trk proteins: what are they and how to test for them. Hum Pathol. 2021;112:59\u201369.","journal-title":"Hum Pathol"},{"key":"1284_CR30","doi-asserted-by":"publisher","first-page":"654387","DOI":"10.3389\/fmolb.2021.654387","volume":"8","author":"S Wu","year":"2021","unstructured":"Wu S, Shi X, Ren X, Li K, Pang J, Liang Z. Evaluation of NTRK Gene Fusion by Five Different Platforms in Triple-Negative Breast Carcinoma. Front Mol Biosci. 2021;8:654387.","journal-title":"Front Mol Biosci"},{"issue":"1","key":"1284_CR31","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s12253-017-0379-z","volume":"26","author":"RM Ghali","year":"2020","unstructured":"Ghali RM, Al-Mutawa MA, Ebrahim BH, Jrah HH, Zaied S, Bhiri H, et al. Progesterone Receptor (PGR) Gene Variants Associated with Breast Cancer and Associated Features: a Case-Control Study. Pathol Oncol Res. 2020;26(1):141\u20137.","journal-title":"Pathol Oncol Res"},{"issue":"4","key":"1284_CR32","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1158\/1055-9965.EPI-05-0679","volume":"15","author":"KA Pooley","year":"2006","unstructured":"Pooley KA, Healey CS, Smith PL, Pharoah PD, Thompson D, Tee L,\u00a0 et al. Association of the progesterone receptor gene with breast cancer risk: a single-nucleotide polymorphism tagging approach. Cancer Epidemiol Biomarkers Prev. 2006;15(4):675\u201382.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"1284_CR33","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41523-021-00250-8","volume":"7","author":"EM da Silva","year":"2021","unstructured":"Silva EM, Selenica P, Vahdatinia M, Pareja F, Paula ADC, Ferrando L, et al.\u00a0TERT promoter hotspot mutations and gene amplification in metaplastic breast cancer. NPJ Breast Cancer. 2021;7(1):43.","journal-title":"NPJ Breast Cancer"},{"issue":"3","key":"1284_CR34","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1007\/s12282-017-0825-5","volume":"25","author":"T Shimoi","year":"2018","unstructured":"Shimoi T, Yoshida M, Kitamura Y, Yoshino T, Kawachi A,\u00a0 Shimomura A, et al. TERT promoter hotspot mutations in breast cancer. Breast Cancer. 2018;25(3):292\u20136.","journal-title":"Breast Cancer"},{"issue":"4","key":"1284_CR35","doi-asserted-by":"publisher","first-page":"371 384","DOI":"10.1038\/ng.2566","volume":"45","author":"SE Bojesen","year":"2013","unstructured":"Bojesen SE, Pooley KA, Johnatty SE, Beesley J, Michailidou K, Tyrer JP, et al. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet. 2013;45(4):371\u201384.","journal-title":"Nat Genet"},{"issue":"44","key":"1284_CR36","doi-asserted-by":"publisher","first-page":"77540","DOI":"10.18632\/oncotarget.20560","volume":"8","author":"M Gay-Bellile","year":"2017","unstructured":"Gay-Bellile M, V\u00e9ron\u00e8se L, Combes P, Eymard-Pierre E, Kwiatkowski F,\u00a0 Dauplat MM,et al. TERT promoter status and gene copy number gains: effect on TERT expression and association with prognosis in breast cancer. Oncotarget. 2017;8(44):77540\u201351.","journal-title":"Oncotarget"},{"issue":"3","key":"1284_CR37","first-page":"681","volume":"29","author":"Y Murofushi","year":"2006","unstructured":"Murofushi Y, Nagano S, Kamizono J, Takahashi T, Fujiwara H, Komiya S, et al. Cell cycle-specific changes in hTERT promoter activity in normal and cancerous cells in adenoviral gene therapy: a promising implication of telomerase-dependent targeted cancer gene therapy. Int J Oncol. 2006;29(3):681\u20138.","journal-title":"Int J Oncol"},{"issue":"1","key":"1284_CR38","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13073-016-0324-x","volume":"8","author":"MA Jafri","year":"2016","unstructured":"Jafri MA, Ansari SA, Alqahtani MH, Shay JW. Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies. Genome Med. 2016;8(1):69.","journal-title":"Genome Med"},{"issue":"3","key":"1284_CR39","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.ccell.2018.08.008","volume":"34","author":"P Razavi","year":"2018","unstructured":"Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, Vasan N, et al. The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. Cancer Cell. 2018;34(3):427\u201338.","journal-title":"Cancer Cell"},{"key":"1284_CR40","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.3389\/fimmu.2019.01113","volume":"10","author":"H Chen","year":"2019","unstructured":"Chen H, Chong W, Wu Q, Yao Y, Mao M, Wang X. Association of LRP1B Mutation With Tumor Mutation Burden and Outcomes in Melanoma and Non-small Cell Lung Cancer Patients Treated With Immune Check-Point Blockades. Front Immunol. 2019;10:1113.","journal-title":"Front Immunol"},{"key":"1284_CR41","doi-asserted-by":"crossref","unstructured":"Brown LC, Tucker MD, Sedhom R, Schwartz EB, Zhu J, Kao C, et al. LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types. J Immunother Cancer.\u00a02021;9(3):e001792.","DOI":"10.1136\/jitc-2020-001792"},{"issue":"4","key":"1284_CR42","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/nsmb.1400","volume":"15","author":"S Tu","year":"2008","unstructured":"Tu S, Teng YC, Yuan C, Wu YT, Chan MY, Cheng AN, et al. The ARID domain of the H3K4 demethylase RBP2 binds to a DNA CCGCCC motif. Nat Struct Mol Biol. 2008;15(4):419\u201321.","journal-title":"Nat Struct Mol Biol"},{"issue":"7248","key":"1284_CR43","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/nature08036","volume":"459","author":"GG Wang","year":"2009","unstructured":"Wang GG, Song J, Wang Z, Dormann HL, Casadio F, Li H, et al. Haematopoietic malignancies caused by dysregulation of a chromatin-binding PHD finger. Nature. 2009;459(7248):847\u201351.","journal-title":"Nature"},{"key":"1284_CR44","doi-asserted-by":"crossref","unstructured":"Li S, He J, Liao X, He Y, Chen R, Chen J, et al. Fbxo22 inhibits metastasis in triple-negative breast cancer through ubiquitin modification of KDM5A and regulation of H3K4me3 demethylation. Cell Biol Toxicol.\u00a02022.","DOI":"10.1007\/s10565-022-09754-w"},{"issue":"Suppl 2","key":"1284_CR45","doi-asserted-by":"publisher","first-page":"e000612","DOI":"10.1136\/esmoopen-2019-000612","volume":"4","author":"U Lassen","year":"2019","unstructured":"Lassen U. How I treat NTRK gene fusion-positive cancers. ESMO Open. 2019;4(Suppl 2):e000612.","journal-title":"ESMO Open"}],"container-title":["Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-022-01284-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13000-022-01284-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-022-01284-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,3]],"date-time":"2023-12-03T20:01:34Z","timestamp":1701633694000},"score":1,"resource":{"primary":{"URL":"https:\/\/diagnosticpathology.biomedcentral.com\/articles\/10.1186\/s13000-022-01284-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,31]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1284"],"URL":"https:\/\/doi.org\/10.1186\/s13000-022-01284-7","relation":{},"ISSN":["1746-1596"],"issn-type":[{"value":"1746-1596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,31]]},"assertion":[{"value":"15 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"In accordance with the institutional ethics guidelines, under permission from Ethics Committee of the Third Affiliated Hospital of Soochow University Institutional Review Board (ID: 2020-41).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None declared. Patient consent for publication. Not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"101"}}